Cargando…

BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification

The nuclear deubiquitylase BRCA1-associated protein 1 (BAP1) is frequently inactivated in malignant pleural mesothelioma (MPM) and germline BAP1 mutation predisposes to cancers including MPM. To explore the influence on cell physiology and drug sensitivity, we sequentially edited a predisposition mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnett, Sarah E., Kenyani, Jenna, Tripari, Martina, Butt, Zohra, Grosman, Rudi, Querques, Francesca, Shaw, Liam, Silva, Luisa C., Goate, Zoe, Marciniak, Stefan J., Rassl, Doris M., Jackson, Richard, Lian, Lu-Yun, Szlosarek, Peter W., Sacco, Joseph J., Coulson, Judy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150242/
https://www.ncbi.nlm.nih.gov/pubmed/36669126
http://dx.doi.org/10.1158/1541-7786.MCR-22-0635
_version_ 1785035328366575616
author Barnett, Sarah E.
Kenyani, Jenna
Tripari, Martina
Butt, Zohra
Grosman, Rudi
Querques, Francesca
Shaw, Liam
Silva, Luisa C.
Goate, Zoe
Marciniak, Stefan J.
Rassl, Doris M.
Jackson, Richard
Lian, Lu-Yun
Szlosarek, Peter W.
Sacco, Joseph J.
Coulson, Judy M.
author_facet Barnett, Sarah E.
Kenyani, Jenna
Tripari, Martina
Butt, Zohra
Grosman, Rudi
Querques, Francesca
Shaw, Liam
Silva, Luisa C.
Goate, Zoe
Marciniak, Stefan J.
Rassl, Doris M.
Jackson, Richard
Lian, Lu-Yun
Szlosarek, Peter W.
Sacco, Joseph J.
Coulson, Judy M.
author_sort Barnett, Sarah E.
collection PubMed
description The nuclear deubiquitylase BRCA1-associated protein 1 (BAP1) is frequently inactivated in malignant pleural mesothelioma (MPM) and germline BAP1 mutation predisposes to cancers including MPM. To explore the influence on cell physiology and drug sensitivity, we sequentially edited a predisposition mutation (w-) and a promoter trap (KO) into human mesothelial cells. BAP1(w-/KO) MeT5A cells express less BAP1 protein and phenocopy key aspects of BAP1 loss in MPM. Stable isotope labeling with amino acids in cell culture–mass spectrometry revealed evidence of metabolic adaptation, with concomitant alteration of cellular metabolites. In MeT5A, BAP1 deficiency reduces glycolytic enzyme levels but increases enzymes involved in the tricarboxylic acid cycle and anaplerotic pathways. Notably both argininosuccinate synthase 1 (ASS1), essential for cellular synthesis of arginine, and its substrate aspartate, are elevated in BAP1(w-/KO) MeT5A cells. Likewise, ASS1 expression is higher in BAP1-altered MPM cell lines, and inversely correlates with BAP1 in The Cancer Genome Atlas MESO dataset. Elevated ASS1 is also evident by IHC staining in epithelioid MPM lacking nuclear BAP1 expression, with improved survival among patients with BAP1-negative/ASS1-expressing tumors. Alterations in arginine metabolism may sensitize cells to metabolic drugs and we find that BAP1-negative/ASS1-expressing MPM cell lines are more sensitive to ASS1 inhibition, although not to inhibition of purine synthesis by mizoribine. Importantly, BAP1(w-/KO) MeT5A become desensitized to arginine deprivation by pegylated arginine deiminase (ADI-PEG20), phenocopying BAP1-negative/ASS1-expressing MPM cell lines. IMPLICATIONS: Our data reveal an interrelationship between BAP1 and arginine metabolism, providing a potential means of identifying patients with epithelioid MPM likely to benefit from ADI-PEG20.
format Online
Article
Text
id pubmed-10150242
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-101502422023-05-02 BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification Barnett, Sarah E. Kenyani, Jenna Tripari, Martina Butt, Zohra Grosman, Rudi Querques, Francesca Shaw, Liam Silva, Luisa C. Goate, Zoe Marciniak, Stefan J. Rassl, Doris M. Jackson, Richard Lian, Lu-Yun Szlosarek, Peter W. Sacco, Joseph J. Coulson, Judy M. Mol Cancer Res Cancer Genes and Networks The nuclear deubiquitylase BRCA1-associated protein 1 (BAP1) is frequently inactivated in malignant pleural mesothelioma (MPM) and germline BAP1 mutation predisposes to cancers including MPM. To explore the influence on cell physiology and drug sensitivity, we sequentially edited a predisposition mutation (w-) and a promoter trap (KO) into human mesothelial cells. BAP1(w-/KO) MeT5A cells express less BAP1 protein and phenocopy key aspects of BAP1 loss in MPM. Stable isotope labeling with amino acids in cell culture–mass spectrometry revealed evidence of metabolic adaptation, with concomitant alteration of cellular metabolites. In MeT5A, BAP1 deficiency reduces glycolytic enzyme levels but increases enzymes involved in the tricarboxylic acid cycle and anaplerotic pathways. Notably both argininosuccinate synthase 1 (ASS1), essential for cellular synthesis of arginine, and its substrate aspartate, are elevated in BAP1(w-/KO) MeT5A cells. Likewise, ASS1 expression is higher in BAP1-altered MPM cell lines, and inversely correlates with BAP1 in The Cancer Genome Atlas MESO dataset. Elevated ASS1 is also evident by IHC staining in epithelioid MPM lacking nuclear BAP1 expression, with improved survival among patients with BAP1-negative/ASS1-expressing tumors. Alterations in arginine metabolism may sensitize cells to metabolic drugs and we find that BAP1-negative/ASS1-expressing MPM cell lines are more sensitive to ASS1 inhibition, although not to inhibition of purine synthesis by mizoribine. Importantly, BAP1(w-/KO) MeT5A become desensitized to arginine deprivation by pegylated arginine deiminase (ADI-PEG20), phenocopying BAP1-negative/ASS1-expressing MPM cell lines. IMPLICATIONS: Our data reveal an interrelationship between BAP1 and arginine metabolism, providing a potential means of identifying patients with epithelioid MPM likely to benefit from ADI-PEG20. American Association for Cancer Research 2023-05-01 2023-01-20 /pmc/articles/PMC10150242/ /pubmed/36669126 http://dx.doi.org/10.1158/1541-7786.MCR-22-0635 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
spellingShingle Cancer Genes and Networks
Barnett, Sarah E.
Kenyani, Jenna
Tripari, Martina
Butt, Zohra
Grosman, Rudi
Querques, Francesca
Shaw, Liam
Silva, Luisa C.
Goate, Zoe
Marciniak, Stefan J.
Rassl, Doris M.
Jackson, Richard
Lian, Lu-Yun
Szlosarek, Peter W.
Sacco, Joseph J.
Coulson, Judy M.
BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
title BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
title_full BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
title_fullStr BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
title_full_unstemmed BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
title_short BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
title_sort bap1 loss is associated with higher ass1 expression in epithelioid mesothelioma: implications for therapeutic stratification
topic Cancer Genes and Networks
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150242/
https://www.ncbi.nlm.nih.gov/pubmed/36669126
http://dx.doi.org/10.1158/1541-7786.MCR-22-0635
work_keys_str_mv AT barnettsarahe bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT kenyanijenna bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT triparimartina bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT buttzohra bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT grosmanrudi bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT querquesfrancesca bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT shawliam bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT silvaluisac bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT goatezoe bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT marciniakstefanj bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT rassldorism bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT jacksonrichard bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT lianluyun bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT szlosarekpeterw bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT saccojosephj bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification
AT coulsonjudym bap1lossisassociatedwithhigherass1expressioninepithelioidmesotheliomaimplicationsfortherapeuticstratification